(News Bulletin 247) – While lowering its target price from 117 to 111 euros, Invest Securities reiterates its ‘buy’ opinion on bioMérieux, judging that ‘the reservoir of growth seems far from being exhausted’ and that ‘the group has resources to get active in the M&A field.
The research department explains the moderate market sanction on Friday (-1%) by ‘lower than expected margin levels, partially offset by remarkable sales growth, and in particular from the MDx division’.
According to Invest Securities, the 2023 objectives seem easily achievable and the first half confirms the solid positioning of the group specializing in in vitro diagnostics ‘in the world of After’.
Copyright (c) 2023 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
